Rockwell Medical Reports First Quarter Results

WIXOM, Mich., May 09, 2017 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the quarter ended March 31, 2017.